The curves demonstrate that when the threshold probability for EGFR mutation is set at 10%, applying our logistic regression model to predict EGFR mutation status in NSCLC patients yields more net benefit compared to strategies of either universal treatment or no treatment at all (Huang et al., 2016), particularly evident with a wider net benefit range observed in the validation cohort, highlighting the clinical utility and practical applicability of our predictive model. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.